Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|New England Journal of Medicine|2016Cited by 768
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Moupali Das et al.|New England Journal of Medicine|2024Cited by 471
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|Obstetrical & Gynecological Survey|2016Cited by 373
Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trialElizabeth R. Brown, Craig W. Hendrix, Ariane van der Straten et al.|Journal of the International AIDS Society|2020Cited by 78
Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention TrialElizabeth Montgomery, Sarah T. Roberts, Gonasagrie Nair et al.|AIDS and Behavior|2019Cited by 47